Rocket Pharmaceuticals Reports First Quarter 2026 Results and Advances Cardiovascular Gene Therapy Pipeline
Rocket Pharmaceuticals, a commercial-stage biotechnology company focused on developing genetic therapies for rare and life-threatening disorders, has announced its financial and operational results for the first quarter ended March 31, 2026. The company highlighted continued progress across its cardiovascular gene therapy programs, the advancement of multiple clinical studies, and the recent accelerated approval of KRESLADI™ for severe leukocyte adhesion deficiency-I (LAD-I).
Rocket Pharmaceuticals also emphasized the strengthening of its financial position following the monetization of its Rare Pediatric Disease Priority Review Voucher, a transaction that generated $180 million in non-dilutive capital and extended the company’s projected cash runway into the second quarter of 2028.
Chief Executive Officer Gaurav Shah said the company maintained momentum during the quarter by continuing to advance its cardiovascular pipeline while also achieving an important regulatory milestone with the FDA approval of KRESLADI.
According to Shah, the company remains focused on disciplined execution across its portfolio and expects to provide additional updates later in 2026 regarding its Danon disease program.
One of the most significant developments reported during the quarter involved Rocket’s lead cardiovascular gene therapy candidate RP-A501 for Danon disease, a rare and severe genetic disorder that affects the heart, muscles, and other organs. The company confirmed that dosing remains on track for the initial three-patient cohort in the pivotal Phase 2 study evaluating RP-A501.
Rocket had previously disclosed that the U.S. Food and Drug Administration lifted the clinical hold on the Phase 2 trial in less than three months. Under the agreement reached with the FDA, the company is administering treatment to three additional patients using a recalibrated dose of 3.8 × 10¹³ GC/kg, combined with a modified immunomodulatory regimen and a minimum four-week interval between patient dosing.
Following completion of treatment for these patients, Rocket plans to continue discussions with the FDA regarding the next steps for the Phase 2 pivotal study. The company anticipates sharing a broader update on the Danon disease program during the second half of 2026.
Danon disease remains an area of high unmet medical need because the condition frequently leads to progressive cardiomyopathy and heart failure at a young age. Current treatment options are limited, making gene therapy approaches an important area of investigation for affected patients and families.
Rocket Pharmaceuticals also reported continued engagement with the FDA regarding RP-A601, the company’s investigational gene therapy candidate for plakophilin-2 arrhythmogenic cardiomyopathy, commonly known as PKP2-ACM. The therapy is currently being evaluated in an ongoing Phase 1 clinical study that remains open and actively enrolling patients.
The company stated that discussions with the FDA are focused on alignment regarding the design of a potential pivotal Phase 2 trial for RP-A601. Meanwhile, the ongoing Phase 1 study is intended to further characterize the biological activity of the therapy across a wider range of disease severity.
PKP2-ACM is a rare inherited cardiac disorder associated with arrhythmias, heart muscle damage, and increased risk of sudden cardiac death. As with several rare cardiovascular diseases, available treatment options remain limited, creating strong interest in novel gene therapy strategies capable of addressing the underlying genetic cause.
In addition to its existing cardiovascular programs, Rocket is also progressing RP-A701, an investigational therapy for BAG3-associated dilated cardiomyopathy, or BAG3-DCM. The company confirmed that startup activities are continuing for the first-in-human Phase 1 clinical trial evaluating the therapy.
The planned multi-center, dose-escalation study is designed to assess the safety, biological activity, and preliminary efficacy of RP-A701 in adult patients with BAG3-DCM. Rocket expects dosing of the first patient in the study to begin in mid-2026.
BAG3-associated dilated cardiomyopathy is another rare inherited heart condition linked to progressive heart failure and impaired cardiac function. The disease is caused by mutations in the BAG3 gene, which plays a role in maintaining muscle cell function and structural integrity.
Beyond its cardiovascular pipeline, Rocket achieved a major regulatory milestone during the quarter with the FDA’s accelerated approval of KRESLADI™ (marnetegragene autotemcel) for pediatric patients with severe leukocyte adhesion deficiency-I.
The approval, granted in March 2026, covers pediatric patients with severe LAD-I caused by biallelic variants in the ITGB2 gene who do not have an available human leukocyte antigen-matched sibling donor for allogeneic hematopoietic stem cell transplantation.
The indication received accelerated approval based on increases in neutrophil CD18 and CD11a surface expression observed during clinical evaluation. Leukocyte adhesion deficiency-I is a rare and life-threatening inherited immune disorder that severely impairs the body’s ability to fight infections.
The approval represented a significant achievement for Rocket Pharmaceuticals because it marked the company’s transition further into the commercial-stage biotechnology sector while validating its broader gene therapy platform.
Shortly after the approval, Rocket announced on April 28, 2026, that it had entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $180 million. The transaction provided the company with additional non-dilutive capital intended to support ongoing pipeline development and operational activities.
In addition to clinical and regulatory updates, Rocket Pharmaceuticals released detailed first-quarter financial results.
As of March 31, 2026, the company reported cash, cash equivalents, and investments totaling $144.4 million, excluding proceeds from the later Priority Review Voucher transaction.
Research and development expenses for the quarter were $31.5 million, compared with $35.9 million during the same period in 2025. Rocket stated that the $4.4 million decrease was primarily driven by lower manufacturing and development costs, reductions in direct material expenses, and lower compensation-related expenses associated with decreased research and development headcount.
These reductions were partially offset by increases in clinical trial expenses and professional service fees as the company continued advancing its pipeline programs. Rocket noted that the overall reduction reflects disciplined resource allocation following a recent organizational realignment.
General and administrative expenses also declined significantly during the quarter. Rocket reported G&A expenses of $17.1 million for the first quarter of 2026, compared with $28.4 million during the prior-year period.
The decrease was largely attributed to lower legal expenses following a legal settlement in 2025, reduced commercial preparation costs, lower launch-related spending, and lower compensation expenses resulting from reduced administrative headcount. These savings were partially offset by increased milestone-related expenses.
Rocket Pharmaceuticals reported a net loss of $47.6 million, or $0.42 per share, for the first quarter of 2026. This compares with a net loss of $61.3 million, or $0.56 per share, during the first quarter of 2025.
The company also reported that 109,123,671 shares of common stock were outstanding as of March 31, 2026.
Looking ahead, Rocket believes its current financial resources, combined with proceeds from the Priority Review Voucher sale, will be sufficient to support operations into the second quarter of 2028.
The extended cash runway provides the company with additional flexibility as it continues advancing multiple clinical-stage cardiovascular gene therapy programs, expands commercial activities following the approval of KRESLADI, and pursues future regulatory and development milestones.
Rocket Pharmaceuticals remains one of several biotechnology companies seeking to establish gene therapies as transformative treatments for rare inherited diseases. The company’s focus on cardiovascular genetic disorders distinguishes it within the broader gene therapy sector, where many developers continue targeting neuromuscular, hematologic, metabolic, and immunologic conditions.
As clinical development progresses across the company’s pipeline, investors and clinicians will continue closely monitoring upcoming data updates, regulatory interactions, and enrollment progress in the company’s pivotal and early-stage studies throughout 2026 and beyond.
About KRESLADI™
KRESLADI™ (marnetegragene autotemcel) is an autologous hematopoietic stem cell-based gene therapy designed to address the underlying genetic cause of severe leukocyte adhesion deficiency-I (LAD-I), an ultra-rare, life-threatening pediatric immunodeficiency. The therapy utilizes ex vivo lentiviral vector-mediated gene transfer to introduce a functional copy of the ITGB2 gene into a patient’s hematopoietic stem cells, enabling expression of CD18 and restoration of leukocyte adhesion and migration.
KRESLADI is administered as a one-time intravenous infusion following myeloablative conditioning. In clinical studies, treatment with KRESLADI resulted in increased neutrophil CD18 and CD11a surface expression, supporting the biological activity of the therapy and forming the basis for accelerated approval. Continued approval may be contingent upon verification and description of clinical benefit through ongoing clinical follow-up and additional post-marketing data collection.
Severe LAD-I is characterized by recurrent, serious bacterial and fungal infections beginning in early infancy and is associated with high early-childhood mortality without effective treatment.
